Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients

Inclusion Criteria: * Diagnosis of pediatric glaucoma or ocular hypertension. * Qualifying mean IOP at the Eligibility Visit in at least one eye. * Written informed consent, including assent when applicable, MUST be obtained from the parent or legally authorized representative prior to any procedure specified in the protocol, including screening procedures. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Females of childbearing potential who are pregnant, intend to become pregnant during the study period, breast feeding, or not using any form of birth control measures. * History of chronic, recurrent or severe inflammatory eye disease. * Ocular trauma requiring medical attention within the past 3 months prior to the Screening Visit. * Ocular infection or ocular inflammation within the past 30 days prior to the Screening Visit. * Clinically significant or progressive retinal disease. * Severe ocular pathology (including severe dry eye) that, in the opinion of the Investigator, would preclude the administration of a topical prostaglandin analog or a topical beta-blocker. * Intraocular surgery in the study eye within 30 days prior to the Screening Visit. * Any abnormality preventing reliable applanation tonometry. * Other protocol-defined exclusion criteria may apply.